Fluticasone/theophylline- VecturaAlternative Names: ADC 4022/fluticasone; SKP 2075; Theophylline/fluticasone - Vectura
Latest Information Update: 14 Jul 2016
At a glance
- Originator Pulmagen Therapeutics
- Developer Vectura
- Class Anti-inflammatories; Antiasthmatics; Antibronchitics; Bronchodilators; Corticosteroids; Xanthines
- Mechanism of Action Glucocorticoid receptor agonists; Histone deacetylase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease